(PharmaNewsWire.Com, September 11, 2017 ) Healthcare-associated infections (HAIs) are a major threat to patient safety. HAIs occur in hospitalized patients, and are not present at the time of admission. The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories: catheter-associated urinary tract infection (CAUTI), central line-associated bloodstream infection (CLABSI), hospital-associated pneumonia (HAP)/ventilator-associated pneumonia (VAP), and surgical site infection (SSI). Infections caused by Gram-negative bacteria are of particular public health concern, since they are at the root of approximately 30-70% of HAIs across the globe.
GlobalData epidemiologists forecast that the suspected incident cases of CAUTI, CLABSI, HAP/VAP, and SSI in the 7MM will grow by an Annual Growth Rate (AGR) of 0.60% per year over the next 10 years, from 2,592,739 cases in 2016 to 2,747,836 in 2026. In the 7MM, the US will have the highest number of suspected incident cases, with 1,311,068 in 2016, while Japan will have the lowest number of suspected incident cases, with 84,847 in 2016.
GlobalData epidemiologists forecast that the diagnosed incident cases of Gram-negative CAUTI, CLABSI, HAP/VAP, and SSI in the 7MM will grow by an AGR of 0.55% per year over the next 10 years, from 1,116,853 cases in 2016 to 1,178,754 cases in 2026. In the 7MM, the US will have the highest number of diagnosed incident cases, with 505,544 in 2016, while Japan will have the lowest number of diagnosed incident cases, with 41,245 in 2016.
GlobalData epidemiologists utilized primary research and comprehensive, country-specific data from national nosocomial surveillance systems and peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast for the suspected incident cases of HAIs and diagnosed incident cases of Gram-negative HAIs. In this analysis, GlobalData epidemiologists provide detailed, clinically relevant segmentations for suspected and diagnosed incident cases of Gram-negative HAIs.
Scope
-The Healthcare-Associated Gram-Negative Infections EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of healthcare-associated Gram-negative infections in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the suspected incident cases of healthcare-associated infections (HAIs) and diagnosed incident cases of Gram-negative HAIs in acute care, in men and women combined, ages 18 years and older, segmented by select infection sites: catheter-associated urinary tract infection (CAUTI), central line-associated blood stream infection (CLABSI), hospital-associated pneumonia (HAP)/ventilator-associated pneumonia (VAP), and surgical site infection (SSI). Infection site-specific diagnosed incident cases of Gram-negative HAIs are further segmented by causative agent (Acinetobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa). -The Healthcare-Associated Gram-Negative Infections epidemiology report is written and developed by Masters-and PhD-level epidemiologists. -The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
The Healthcare-Associated Gram-Negative Infections EpiCast report will allow you to- -Develop business strategies by understanding the trends shaping and driving the global Gram-negative HAI market. -Quantify patient populations in the global Gram-negative HAI market to improve product design, pricing, and launch plans. -Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Gram-negative HAI therapeutics in each of the markets covered. -Identify the percentage of suspected and diagnosed incident cases of Gram-negative HAIs by various clinical segmentations. Table of Content List of Tables 3 List of Figures 3 2 Healthcare-Associated Gram-Negative Infections: Executive Summary 4 2.1 Related Reports 6 2.2 Upcoming Reports 6 3 Epidemiology 7 3.1 Disease Background 7 3.2 Risk Factors and Comorbidities 7 3.3 Global and Historical Trends 8 3.3.1 US 9 3.3.2 5EU 9 3.3.3 Japan 10 3.4 Forecast Methodology 10 3.4.1 Sources 11 3.4.2 Forecast Assumptions and Methods 15 3.5 Epidemiological Forecast for Suspected HAIs and Gram-Negative HAIs (2016-2026) 23 3.5.1 Suspected Incident Cases of Select HAIs 23 3.5.2 Diagnosed Incident Cases of Select Gram-Negative HAIs 24 3.5.3 Suspected Incident Cases of Select HAIs by Infection Site 25 3.5.4 Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site 26 3.5.5 Diagnosed Incident Cases of Select Gram-Negative HAIs by Causative Agent 27 3.6 Discussion 31 3.6.1 Epidemiological Forecast Insight 31 3.6.2 Limitations of the Analysis 32 3.6.3 Strengths of the Analysis 33 4 Appendix 34 4.1 Bibliography 34 4.2 Primary Research-Key Opinion Leaders Interviewed for this Report 38 4.3 Primary Research-Prescriber Survey 41 4.4 About the Authors 42 4.4.1 Epidemiologist 42 4.4.2 Reviewers 42 4.4.3 Global Director of Therapy Analysis and Epidemiology 43 4.4.4 Global Head and EVP of Healthcare Operations and Strategy 43 4.5 About GlobalData 44 4.6 Contact Us 44 4.7 Disclaimer 44 Inquire for Report at http://www.reportsweb.com/inquiry&RW00011037844/buying
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
